Mike Wenzel, Felix Martin Preißer, Robert Benedikt Höh, Maria Schröder, Christoph Würnschimmel, Thomas Steuber, Hans Heinzer, Séverine Banek, Marit Ahrens, Andreas Becker, Pierre I. Karakiewicz, Felix Chun, Luis A. Kluth, Philipp Mandel
- Background: To evaluate the impact of time to castration resistance (TTCR) in metastatic hormone-sensitive prostate cancer (mHSPC) patients on overall survival (OS) in the era of combination therapies for mHSPC.
Material and Methods: Of 213 mHSPC patients diagnosed between 01/2013-12/2020 who subsequently developed metastatic castration resistant prostate cancer (mCRPC), 204 eligible patients were analyzed after having applied exclusion criteria. mHSPC patients were classified into TTCR <12, 12-18, 18-24, and >24 months and analyzed regarding OS. Moreover, further OS analyses were performed after having developed mCRPC status according to TTCR. Logistic regression models predicted the value of TTCR on OS.
Results: Median follow-up was 34 months. Among 204 mHSPC patients, 41.2% harbored TTCR <12 months, 18.1% for 12-18 months, 15.2% for 18-24 months, and 25.5% for >24 months. Median age was 67 years and median PSA at prostate cancer diagnosis was 61 ng/ml. No differences in patient characteristics were observed (all p>0.05). According to OS, TTCR <12 months patients had the worst OS, followed by TTCR 12-18 months, 18-24 months, and >24 months, in that order (p<0.001). After multivariable adjustment, a 4.07-, 3.31-, and 6.40-fold higher mortality was observed for TTCR 18-24 months, 12-18 months, and <12 months patients, relative to TTCR >24 months (all p<0.05). Conversely, OS after development of mCRPC was not influenced by TTCR stratification (all p>0.05).
Conclusion: Patients with TTCR <12 months are at the highest OS disadvantage in mHSPC. This OS disadvantage persisted even after multivariable adjustment. Interestingly, TTCR stratified analyses did not influence OS in mCRPC patients.
MetadatenAuthor: | Mike WenzelORCiDGND, Felix Martin PreißerORCiDGND, Robert Benedikt HöhORCiDGND, Maria Schröder, Christoph WürnschimmelORCiDGND, Thomas SteuberGND, Hans Heinzer, Séverine BanekGND, Marit AhrensORCiDGND, Andreas BeckerGND, Pierre I. Karakiewicz, Felix ChunORCiDGND, Luis A. KluthORCiDGND, Philipp MandelORCiDGND |
---|
URN: | urn:nbn:de:hebis:30:3-611817 |
---|
DOI: | https://doi.org/10.3389/fonc.2021.659135 |
---|
ISSN: | 2234-943X |
---|
Parent Title (English): | Frontiers in oncology |
---|
Publisher: | Frontiers Media |
---|
Place of publication: | Lausanne |
---|
Document Type: | Article |
---|
Language: | English |
---|
Date of Publication (online): | 2021/04/23 |
---|
Date of first Publication: | 2021/04/23 |
---|
Publishing Institution: | Universitätsbibliothek Johann Christian Senckenberg |
---|
Release Date: | 2021/06/23 |
---|
Tag: | CRPC; castration resistance; metastatic prostate cancer; mortality; survival |
---|
Volume: | 11 |
---|
Issue: | art. 659135 |
---|
Page Number: | 8 |
---|
First Page: | 1 |
---|
Last Page: | 8 |
---|
HeBIS-PPN: | 484966731 |
---|
Institutes: | Medizin |
---|
Dewey Decimal Classification: | 6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit |
---|
Sammlungen: | Universitätspublikationen |
---|
Open-Access-Publikationsfonds: | Medizin |
---|
Licence (German): | Creative Commons - Namensnennung 4.0 |
---|